Literature DB >> 17286590

A beta oligomers - a decade of discovery.

Dominic M Walsh1, Dennis J Selkoe.   

Abstract

Converging lines of evidence suggest that progressive accumulation of the amyloid beta-protein (A beta) plays a central role in the genesis of Alzheimer's disease, but it was long assumed that A beta had to be assembled into extracellular amyloid fibrils to exert its cytotoxic effects. Over the past decade, data have emerged from the use of synthetic A beta peptides, cell culture models, beta-amyloid precursor protein transgenic mice and human brain to suggest that pre-fibrillar, diffusible assemblies of A beta are also deleterious. Although the precise molecular identity of these soluble toxins remains unsettled, accumulating evidence suggests that soluble forms of A beta are indeed the proximate effectors of synapse loss and neuronal injury. Here we review recent progress in understanding the role of soluble oligomers in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17286590     DOI: 10.1111/j.1471-4159.2006.04426.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  713 in total

1.  Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid beta-protein assembly and toxicity.

Authors:  Kenjiro Ono; Margaret M Condron; David B Teplow
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

2.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

Review 3.  Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

4.  Stable and metastable states of human amylin in solution.

Authors:  Allam S Reddy; Lu Wang; Sadanand Singh; Yun L Ling; Lauren Buchanan; Martin T Zanni; James L Skinner; Juan J de Pablo
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

5.  Inhibitors of catalase-amyloid interactions protect cells from beta-amyloid-induced oxidative stress and toxicity.

Authors:  Lila K Habib; Michelle T C Lee; Jerry Yang
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

6.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

Review 7.  Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology.

Authors:  Daniel J Glass; Steven E Arnold
Journal:  Alzheimers Dement       Date:  2011-12-03       Impact factor: 21.566

Review 8.  Prion protein at the crossroads of physiology and disease.

Authors:  Emiliano Biasini; Jessie A Turnbaugh; Ursula Unterberger; David A Harris
Journal:  Trends Neurosci       Date:  2011-12-01       Impact factor: 13.837

Review 9.  Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.

Authors:  Byron Caughey; Gerald S Baron; Bruce Chesebro; Martin Jeffrey
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

10.  Modulation of aggregate size- and shape-distributions of the amyloid-beta peptide by a designed beta-sheet breaker.

Authors:  Luitgard Nagel-Steger; Borries Demeler; Wolfgang Meyer-Zaika; Katrin Hochdörffer; Thomas Schrader; Dieter Willbold
Journal:  Eur Biophys J       Date:  2009-02-24       Impact factor: 1.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.